Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02705339 | Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | May 17, 2016 | clinicaltrials |
| NCT02651506 | Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules | withdrawn | Phase 2 | 0 | St. Joseph's Healthcare HamiltonOTHER | 0 | May 12, 2016 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT00768131 | A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01184287 | A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Tamir Biotechnology, Inc.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT01928160 | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jul 13, 2015 | clinicaltrials |
| NCT00697060 | A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | AmpliMed CorporationINDUSTRY | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00903942 | Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | University of RochesterOTHER | 1 | Apr 27, 2015 | clinicaltrials |
| NCT01048983 | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 5, 2015 | clinicaltrials |
| NCT02297425 | A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Jan 12, 2015 | clinicaltrials |
| NCT01336543 | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Syed JafriOTHER | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01913067 | Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC(CRANIAL) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Jul 24, 2014 | clinicaltrials |
| NCT00112060 | A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Mar 31, 2014 | clinicaltrials |
| NCT01256203 | Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light | withdrawn | Phase 2 | 0 | Pinnacle Biologics Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00256841 | Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy | withdrawn | Phase 1 / Phase 2 | 0 | Clinical Oncology Research AssociatesOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT01533727 | CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2013 | clinicaltrials |
| NCT01504542 | Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Heat BiologicsINDUSTRY | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01674738 | TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV(SELECT-A) | withdrawn | Phase 2 | 0 | Aktion Bronchialkarzinom e.V.OTHER | 0 | Oct 11, 2013 | clinicaltrials |
| NCT01728181 | A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 25, 2013 | clinicaltrials |
| NCT00268255 | Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Apr 16, 2013 | clinicaltrials |
| NCT00386555 | A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel. | withdrawn | Phase 2 | 0 | Arog Pharmaceuticals, Inc.INDUSTRY | 0 | Aug 9, 2012 | clinicaltrials |
| NCT00048087 | Iressa/Docetaxel in Non-Small-Cell Lung Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT01449357 | Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors | withdrawn | Phase 2 | 0 | GenmabINDUSTRY | 0 | Oct 10, 2011 | clinicaltrials |
Data updated 23 days agoSource updated May 17, 2016source: clinicaltrials